ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Selling, General & Admin history
Currency unavailable · from the income statement
No Selling, General & Admin data reported for this period type.
Selling, General & Admin vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $79.08M USD | +23.9% | +14.3% | 110.1% | |
| LTM Mar 2026 | $71.21M USD | +35.2% | +19.9% | 222.0% | |
| LTM Mar 2026 | $56.47M USD | +8.0% | +20.6% | 1399.8% | |
| LTM Mar 2026 | $52.46M USD | -2.3% | +4.4% | 65.8% | |
| LTM Mar 2026 | $43.57M USD | -11.6% | +0.0% | 96.1% | |
| FY2025 | $41.68M USD | — | — | 223.8% | |
| LTM Mar 2026 | $34.74M USD | +87.8% | +52.2% | — | |
| LTM Mar 2026 | $23.59M USD | — | +2.2% | 2560.2% | |
| LTM Mar 2026 | €14.33M EUR | +6.6% | -8.9% | 106.6% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +8.0% | +9.3% | 166.1% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.